CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.1.1. Secondary research
1.1.2. Primary research
1.1.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

3.5. CLINICAL TRIALS

CHAPTER 4 GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast

4.2. PEDIATRICS (AGE 0-18 YEARS)

4.2.1. Market size and forecast

4.3. ADULTS (AGE 19-35 YEARS)

4.3.1. Market size and forecast

CHAPTER 5 BCG VACCINE MARKET, BY COUNTRY

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Growth factors and opportunities
5.1.3. Market size and forecast

5.2. INDIA

5.2.1. Market size and forecast

5.3. CHINA

5.3.1. Market size and forecast

5.4. BANGLADESH

5.4.1. Market size and forecast

5.5. PAKISTAN

5.5.1. Market size and forecast

5.6. INDONESIA

5.6.1. Market size and forecast

5.7. JAPAN

5.7.1. Market size and forecast

5.8. BRAZIL

5.8.1. Market size and forecast

5.9. MEXICO

5.9.1. Market size and forecast

5.10. SOUTH AFRICA

5.10.1. Market size and forecast

5.11. KENYA

5.11.1. Market size and forecast

5.12. THAILAND

5.12.1. Market size and forecast

5.13. ARGENTINA

5.13.1. Market size and forecast

5.14. COLOMBIA

5.14.1. Market size and forecast

5.15. CHILE

5.15.1. Market size and forecast

5.16. SINGAPORE

5.16.1. Market size and forecast

5.17. REST OF THE WORLD

5.17.1. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. CHINA NATIONAL BIOTEC GROUP (A SUBSIDIARY OF CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION)

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. GREENSIGNAL BIO PHARMA LIMITED

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. INTERVAX LTD.

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. JAPAN BCG LABORATORY

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. MERCK & CO., INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. SANOFI PASTEUR

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. SERUM INSTITUTE OF INDIA PVT. LTD.

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. STATENS SERUM INSTITUT

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments